Bio Pharma Dive
JANUARY 19, 2022
Hal Barron, a key figure in GSK's efforts to revitalize its drug research, will step down as its top scientist at a time when the company is feeling heat from investors to deliver faster growth.
World of DTC Marketing
JANUARY 18, 2022
A Mediabistro survey showed that social networks influence more than 40% of people’s health choices. Tik-Tok, Instagram, and other social media channels may soon be overwhelmed with pharma companies’ content, but is it a good idea? People between 18 and 24 years of age tend to discuss health and wellness issues on social networks twice as much as those between the ages of 45 and 54 (getpushing.com), and of those between 18 and 24 years of age, 90% say they trust medical informatio
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Mirror
JANUARY 17, 2022
January 17, 2022 (Davis, CA) – Botanical Solution Inc. (BSI), innovator of sustainable, consistent, and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and the development of a new product pipeline derive
BioPharma Reporter
JANUARY 20, 2022
A new vaccine manufacturing plant has been opened in Cape Town by South Africa president Cyril Ramaphosa this week.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JANUARY 21, 2022
After halting a Phase 3 trial of the drug last year, Roche went digging for more data. What it found led to plans for another trial, but the pharma's hypothesis may rest on shaky ground.
World of DTC Marketing
JANUARY 17, 2022
Thyroid eye disease affects more women than men, although men are more likely to have severe illnesses. The exact prevalence of thyroid eye disease is not known, but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population. So why in the hell is Tepezza running TV ads? Do Millennials know how to market to older consumers?
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
JANUARY 19, 2022
Just months after the venture was unveiled, controversial biotechnology company Altos Labs has officially launched with $3 billion in funding secured from investors. Dubbed an ‘anti-ageing’ company, Altos has gained mainstream attention for its focus on ‘rejuvenation’ and biological reprogramming technology. While the specific research goals have been kept a closely guarded secret, some scientists propose that rejuvenating cells in a lab could be a path to prolonging huma
Bio Pharma Dive
JANUARY 18, 2022
The FDA has extended by three months its review of Bluebird's treatments for beta thalassemia and a rare brain disorder, the latest delay in the company's lengthy road to market in the U.S.
World of DTC Marketing
JANUARY 21, 2022
Omnichannel is the latest buzzword-making rounds within pharma, but omnichannel has no relevance if your message is too promotional or is irrelevant to your audience. The channel IS essential but not as important as your message. 68% of HCPs indicate webinars or webcasts as their most preferred channel to receive information. It is evident that HCPs are extremely time constraint and prefer to engage with pharma organizations on their terms regarding channel, content, and type of devices.
Pharma Times
JANUARY 18, 2022
Cancer Research UK announces clinical trial for most common type of lung cancer
Pharma Mirror
JANUARY 18, 2022
ADELAIDE, Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. Avance Clinical is taking meetings with biotechs to discuss the benefits of conducting trials in Australia, including no IND requirement and an attractive 43.5% rebate,
Bio Pharma Dive
JANUARY 19, 2022
The acquisition will give the Belgian pharma access to an epilepsy drug that won U.S. approval in June 2020 but that Zogenix has struggled to sell.
BioPharma Reporter
JANUARY 17, 2022
Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a âvaccinal effectâ for the treatment of HIV and prevention of malaria.
pharmaphorum
JANUARY 17, 2022
After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics. Under the joint research plan, the Danish giant will work with EraCal to identify novel drug targets relevant for food intake regulation and additional metabolic phenotypes. Although specific details of the collaboration are yet to be released, EraCal has confirmed that the duo will utilise its phenotypic drug discovery platform to id
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Mirror
JANUARY 18, 2022
BARCELONA, Spain, a global biopharmaceutical company focused on skin health, and IRB Barcelona (the Institute for Research in Biomedicine), an independent, international research centre engaged in fundamental and applied biomedical science, announced today a research collaboration to identify new oral treatments for immune-inflammatory skin diseases with remaining high unmet medical needs using molecular glue degraders, a novel therapeutic modality.
Bio Pharma Dive
JANUARY 20, 2022
Frank Clyburn, a Merck veteran and head of the company's human health division, will leave next month to run IFF, following the exit of other top leaders at the drugmaker.
Pharma Times
JANUARY 21, 2022
Psyros Diagnostics has signed an agreement to be acquired by the Swedish company, Prolight Diagnostics AB. Psyros’s ground-breaking Point-of-Care (POC) technology enables the measurement of disease-indicating molecules in extremely low concentrations–in ten minutes or less.
pharmaphorum
JANUARY 18, 2022
Microsoft and CVS Health have announced a new strategic alliance focusing on personalised care and accelerating digital transformation for the benefit of CVS customers and its employees. David Rhew, MD, global chief medical officer and VP of healthcare at Microsoft, tells us, “Using Microsoft technology, CVS Health will develop a more agile, digital-first technology foundation.” Digital innovation and implementation have skyrocketed within healthcare due to the need to adapt quickly
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
JANUARY 20, 2022
Valneva announced yesterday that results from a lab study showed three doses of its inactivated COVID-19 vaccine candidate, VLA2001, neutralized the Omicron variant.
Bio Pharma Dive
JANUARY 19, 2022
Study results show EQRx's drug, which it means to position as a lower-cost alternative to widely used cancer immunotherapies, extended the lives of lung cancer patients. But it's unclear whether that will be enough to sway the FDA.
Pharma Times
JANUARY 18, 2022
The NHS launches world-first study investigating genetic testing for common diseases
pharmaphorum
JANUARY 17, 2022
GlaxoSmithKline (GSK) claims it has rejected three unsolicited, conditional and non-binding proposals from Unilever to acquire GSK Consumer Healthcare in a deal worth approximately $68.4 billion (£50 billion). The Consumer Healthcare business is a Joint Venture between GSK and Pfizer, with GSK holding a majority controlling interest of 68% and Pfizer 32%.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
XTalks
JANUARY 17, 2022
Abbott’s new cardiac mapping platform, EnSite X EP System, has received clearance from the US Food and Drug Administration (FDA) for the treatment of cardiac arrhythmias. The cardiac mapping system incorporates Abbott’s proprietary EnSite Omnipolar Technology (OT), which allows for 360° mapping to generate better and “true” electrograms (EGM) using the Advisor HD Grid Catheter.
Bio Pharma Dive
JANUARY 18, 2022
Ten months after Roche stopped giving the drug to patients in a Phase 3 trial, the pharma is planning a new study on the belief the medicine may help younger adult patients with less advanced disease.
Pharma Times
JANUARY 19, 2022
NICE also aims to make strides in digital, genomic and antimicrobial technologies
pharmaphorum
JANUARY 17, 2022
A World Health Organization (WHO) panel has given the green light to two new drugs to treat COVID-19. US-based Eli Lilly’s baricitinib (Olumiant), a Janus kinase inhibitor, and GlaxoSmithKline and Vir Biotechnology’s sotrovimab, a monoclonal antibody, were recommended in new WHO guidelines, published in the British Medical Journal. . Baricitinib, administered with corticosteroids, was strongly recommended as a treatment for patients with severe or critical illness.
Outsourcing Pharma
JANUARY 20, 2022
An expert from patient solutions firm Trialbee discusses how the social media firm's recent ban on targeted advertising might impact patient recruitment.
Bio Pharma Dive
JANUARY 18, 2022
AbbVie's Rinvoq and Pfizer's Cibinqo are both JAK-inhibiting drugs that are taken orally, a convenience which could help them compete against injectable treatments like Sanofi and Regeneron's Dupixent.
Pharma Times
JANUARY 19, 2022
Imfinzi has shown improvements in the overall survival of patients with biliary tract cancer
pharmaphorum
JANUARY 21, 2022
A third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to researchers. Research led by UCLH, UCL and the Francis Crick Institute found that the booster dose successfully stimulates antibody levels that neutralise Omicron. Details of the study were published in The Lancet this week. UCLH researchers stated that antibodies generated in people who had received only two doses of either the Oxford/AstraZeneca vaccine or the Pfizer/BioNTech vaccin
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
363 
Let's personalize your content